POC testing: the hospital bedside haemostasis market
This article was originally published in Clinica
Coagulation testing products for use at the hospital bedside have been available for over three decades. International Technidyne Corporation (ITC) was the early pioneer, introducing the Hemochron point-of-care (POC) coagulation analyser in the 1970s for use in hospital operating rooms and other sites. Medtronic is another long-time supplier of POC coagulation systems. A number of new companies have since entered the market, including Roche Diagnostics, Pharmanetics (now part of Helena Labs), Instrumentation Laboratory (IL) and i-STAT/Abbott. POC platelet function testing, which is used to monitor patients undergoing platelet inhibitor therapy, comprises a growing segment of the market, and this is being addressed by companies including Siemens, Accumetrics, Helena Labs and Bio/Data.
You may also be interested in...
Sales in the clinical diagnostics market in the rest of world region, which in this analysis includes China and India, totalled $5.4bn in 2010. The market is forecast to grow at 9.9% per year over the 2010-2015 interval. In the ROW region, growth will be driven by rapid adoption of new technologies and increasing utilisation of healthcare resources in developing countries in Asia (particularly China and India) and, to a lesser extent, in Latin America.
Italy is the third-largest clinical diagnostics country market in Europe, with a total market size only slightly smaller than that of France. Italy devoted 9.6% of its gross domestic product (GDP) to healthcare expenditures in 2010, up from 8.7% in 2007, according to statistics from the Organization for Economic Cooperation and Development. This is higher than in the late 1990s and early 2000s, although spending as a percentage of GDP dropped as low as 7.4% in 1995, similar to rates in the UK and Spain.
Germany and France are the number-one and -two markets in Europe for clinical diagnostics products, respectively, each with their own unique characteristics and challenges.